Indeed, targeting key ECM components such as TGF-β and PD-L1 has demonstrated increased ECM remodeling, enhanced CD8+ T cell infiltration, and a shift in macrophage activity towards an anti-tumor phenotype in colon and breast cancer models 891. This evidence concerns the gene CD8A and neoplasm.